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Abstract The bioequivalence and upper digestive tract
transit time of a drinkable solution of 70 mg/100 mL
alendronate was compared to reference tablets. A ran-
domized, single- dose, two-way crossover study of the rate
of urinary recovery of alendronate during 36 h (AE(0–36 h))
by HPLC, in 104 healthy young male volunteers, showed
that AE(0–36 h) and the maximum excretion rate (Rmax)
were within the accepted range of bioequivalence
81.8–105.7 and 81.7–106.2, respectively. To characterize
the oesophageal passage time of the two alendronate for-
mulations, we performed a randomized, controlled study,
in 24 healthy men and women (mean 52 years old), who
took the formulations standing or lying down, by an X-ray
video deglutition system. When taken in the standing
position, both formulations had equal mean transit times
from mouth to stomach and tablet disintegration but data
dispersion was significantly smaller with the liquid form.
When taken in lying position, drinkable alendronate had
shorter and less variable median transit times compared to
the tablets. These results show that the drinkable alendro-
nate formulation is bioequivalent to the tablets and may be
advantageous in patients in whom the transit or disinte-
gration of the tablets is impaired.
Keywords Alendronate  Bioequivalence 
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Introduction
Orally administered bisphosphonates have very critical
absorption profiles that depend on the postdosing fasting
period, which is usually recommended to be at least
30 min. In practice, however, not all patients adhere to this
recommendation, thereby reducing the absorbed fraction of
the drug and jeopardizing the outcome of long-term treat-
ments [1–5]. The critical dependence of bisphosphonate
action on the postdosing fasting period is related to the
chemical and physical properties of these molecules and
their mechanism of absorption.
Bisphosphonates are poorly soluble drugs that cannot
cross the intestinal barrier through cell membranes; many
molecules most probably remain trapped by calcium-
containing proteins in the intercellular space [6]. Absorption
begins when the irritant effect of the molecules causes local
edema, transiently broadening the intercellular spaces and
thus enabling a small portion of the soluble bisphosphonate
molecules to reach the bloodstream [6]. This intricate
absorption mechanism is the reason for the low bioavail-
ability, and local irritation accounts for the typical digestive
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discomfort frequently reported by patients taking oral bis-
phosphonates [7–11].
The convenience of triggering this irritant mechanism
intermittently—once weekly or once monthly rather than
daily—is the rationale for the dosing regimens currently in
use [12]. At the same time, however, the risk of diminished
therapeutic response due to impaired absorption increases
proportionally with the intermittent schedules of adminis-
tration. Consequently, ensuring that soluble bisphosphonate
molecules are available at the site of absorption within
30 min after dosing is essential for therapeutic success in
clinical practice.
Alendronate is currently the most commonly used agent
for the treatment of osteoporosis. Experimental pharma-
cokinetic studies show that absorption can occur in the
stomach and also in the first portion of the small intestine
[13–15]. Quick delivery of the drug to the intestine is
therefore expected to be accompanied by fewer upper
digestive tract symptoms. The oral solution affords soluble
alendronate in a drinkable formulation of pharmaceutical
quality, at a concentration below 1 % -which is not irritant-
and circumvents certain problems described with the solid
formulations [16], for instance: adherence of the tablet to
the digestive mucosa; the challenge to overcome potential
motility obstacles such as hernia, spasm, the body position
of the patient during transit; a slow, variable rate of dis-
integration which causes precipitation or reflux of irritant
particles, acidity [7–10]. The alendronate that is retained in
the stomach during the postdosing fasting period stimulates
absorption through the gastric walls, provided it is not
exposed to interaction with food or with the high mineral
contents of the water [17–21].
The current intermittent schedule of alendronate
administration makes the use of drinkable forms more
comfortable for patients on long-term treatment for osteo-
porosis [12].
In view of the above, we studied the transit in the upper
digestive tract of alendronate given either as tablets or as
drinkable solution in a group of healthy adults, with the
aim to obtain quantitative data on the differences between
the administrations of the two formulations that might
impact its use in clinical practice. Before this study, we
tested the bioequivalence of the two formulations accord-
ing to current regulatory requirements.
Subjects and Methods
Bioequivalence Study
A randomized, single-dose, fasting, two-way crossover study
tested the pharmacokinetic bioequivalence of fast disin-
tegrating alendronate tablets and a drinkable alendronate
solution in subjects recruited at the MTZ Clinical Research
site in Warsaw. The study was conducted according to the
World Medical Association Declaration of Helsinki and
current good clinical practice guidelines and state regula-
tions of Poland. The study protocol was approved by the
Bioethics Committee of the Warsaw Regional Chamber of
Physicians and Dentists and by the European Regulatory
Authority.
The reference product was the 70 mg Fosamax tablet
manufactured by Merck Sharp & Dohme Limited, UK, and
the test product was a 70 mg/100 mL drinkable alendro-
nate solution with thickening agents and orange color and
flavor (Xeolas Pharmaceuticals Ltd., under the license of
Gador SA). The active ingredient of this formulation has
already been described [22].
Prospective participants were informed about the study
and then asked to sign an informed consent form prepared
according to MTZ’s standard operating procedures. Those
who consented were examined and eventually 108 healthy
men were accepted into the study, of which 104 success-
fully completed all stages of the protocol. There were four
withdrawals: one subject withdrew voluntarily, two sub-
jects experienced adverse events (one had increased blood
pressure during period 1 and another one reported an
adverse event not related to the study products during the
washout period), and another subject was tested positive
for unauthorized drugs. Main inclusion criteria were: male
gender, age 18–50 years, and body mass index between
19.0 and 26.0 kg/m2. In addition to other routine criteria,
subjects were required to be able to refrain from smoking
3 days before the beginning of the study until its comple-
tion. Exclusion criteria: current or chronic health problems
and/or drug therapy; a history of allergy, hypocalcemia,
digestive, hepatic or renal disorders; a history of excessive
alcohol consumption ([30 g/day during the previous year);
positive test results for anti-HIV, HBsAg or anti-HCV. In
addition subjects with abnormal blood pressure, pulse or
laboratory test results were excluded from the study.
Participants were randomized according to a numerical
table and were given either a tablet to be swallowed with
240 mL of water or a drinkable solution to be swallowed
with 140 mL of water, to ensure equivalent hydration. No
additional water intake was allowed from 1 h before to 1 h
after dosing, but subjects were afterward administered
2,000 mL of fluids according to a standardized distribution
and a 2,500–3,000 kcal/day diet divided in three meals,
given at 4, 9 and 12 h after dosing.
After a 14 day washout period, study participants were
asked to return to the research center to be given the other
alendronate formulation. On each of the two dosing days,
urine samples were collected at the following time points:
1–1.5 h before dosing, and then after dosing during the
following time intervals: 0 to 0.25; 0.25 to 1 h; 1 to 2 h;
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2 to 3 h; 3 to 4 h; 4 to 6 h; 6 to 8 h; 8 to 12 h; 12 to 24 h
and 24 to 36 h. Each urine sample was collected into a
container from which two 6 mL aliquots were drawn and
placed into plastic tubes. Samples were frozen (-20 C)
and were sent to BioClin Research Laboratories Ltd.
(Ireland), where urinary alendronate concentrations were
determined under blind conditions using a HPLC–fluo-
rescence method (BioClin test method number PR120)
which involves the isolation of alendronate from human
urine by solid-phase extraction. Alendronate was copre-
cipitated with calcium phosphate and then its primary
amino group was derivatized with 2,3-naphtalene dicarb-
oxyaldehyde (NDA) and N-acetyl-D-penicillamine (NAP)
to form the fluorescent derivative. A Shimadzu LC-10AS
(Masons, Dublin) system, a Waters 717 Plus autosampler
(Waters, Dublin) and a Waters 474 fluorescence detector
were used for these measurements. Intra-assay precision
(%CV) was in the 3.95–8.05 % range and mean
percentage accuracy in the 105.5–112.5 % range. The
precision at the lower limit of quantitation (10 ng/mL)
was 5.43 % (defined by %CV), with a 100.1–115.4 %
accuracy. Interassay precision ranged from 4.37 to
14.1 % and mean accuracy ranged from 105.9 to 112.8 %.
The method was validated in the concentration range
10–1,000 ng/mL.
The primary evaluation parameter was the total amount
of drug excreted in the urine from the time of dosing until
36 h after dosing (total AE(0–36 h)) and the maximum uri-
nary excretion rate (Rmax). Secondary parameters were the
amount of drug excreted (AE) and the rate of urinary
excretion (Re) in each collection interval, and the time of
maximum urinary excretion rate (Tmax). Descriptive sta-
tistical analysis was performed and Lund’s method was
used for outlier detection.
The log-transformed total AE(0–36 h) and Rmax were
statistically compared by ANOVA analysis of variance
considering the effect of the treatments, sequence and
period of study. The 90 % confidence interval was tested
by LSMEANS for AE(0–36 h) for the 80–125 % range, and
by Hodges-Lehmann nonparametric methods for Rmax for
the 75–133 % range. WinNonlin version 4.0.1. was used
for the kinetic parameters and SAS version 9.1 for the
statistical calculations.
In order to assess safety, adverse events observed during
the study were reported (using CTCAE v. 3.0 software) and
clinical examinations, including the following measure-
ments and procedures, were performed before and after
each dosing period: pulse, blood pressure, body tempera-
ture, ECG, X-rays, and clinical laboratory determinations
such as urine analysis and hematology, biochemistry,
serology and controlled substance (alcohol, opioids, bar-
biturates, benzodiazepines, amphetamines, cocaine, can-
nabis and nicotine) tests.
Video Deglutition Study in Healthy Adults
This was a prospective, randomized, controlled trial com-
paring the upper digestive tract transit of two alendronate
formulations, conducted according to good clinical practice
guidelines. The study protocol was approved by the Insti-
tutional Ethics Committee of the Maimo´nides University
and by the National Administration of Drugs, Food and
Medical Technology (ANMAT, appl. 4906). After a period
of training in procedures such as subject positioning and
X-ray follow-up of the formulations, the study was opened.
All subjects provided signed informed consent. Twenty-
four healthy adult volunteers, mean age 51.6 years (range
39–68 years), were recruited and randomized according to
an age-cohort table in order to obtain a balanced distribu-
tion of ages within the range. Patients were excluded if:
there was clinical evidence of any chronic disease; they
were hypersensitive to bisphosphonates; they consumed
aspirin, other nonsteroidal anti-inflammatory drugs and/or
alcoholic beverages on a regular basis; or they had expe-
rienced a bone fracture or taken part in any other study
during the 60 days before this study. Both tested formu-
lations were the same as in the previous study. In order to
facilitate the X-ray follow-up, the tablets were drilled with
a fine drill and partly refilled with contrast substance, and
5 mL of the 100 mL drinkable solution were replaced by
contrast media. The in vitro disintegration test of the ori-
ginal and the modified tablets did not show any significant
differences in the dissolution time (data not shown).
Participants were given either the tablet or the drinkable
solution standing or lying in prone position (Fig. 1). Each
subject participated randomly in 3 out of 4 possible
experiments. The formulations were administered under
fasting conditions, which were maintained until the sub-
jects had finished the three series of experiments. Subjects
held the required body position for at least 20 min after
dosing.
All participants were trained to comply with the study
procedures. From a few minutes before dosing until the
experiment was completed, subjects were positioned in
front of a remotely controlled X-ray system of 750 mA,
150 kV, with a high-resolution magnifier and digitizer
(Pinnacle DC 1000 MPEG 2, stored in a HPPavilion
Dv1025IA personal computer), operated by a skilled radi-
ologist. All procedures were recorded and filed for analysis.
In the video analysis, only subjects whose images were
clear for the entire sequence were considered. For statis-
tical purposes, a mouth to stomach time (MST) of 480 s
was considered for tablet disintegration before reaching the
stomach and a disintegration time (DT) of 20 min for
nondisintegration. After the tablet with water and the
drinkable solution had been completely swallowed, MST
was compared for both formulations. The arrival of the tail
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of the swallowed volume was considered, and the drinkable
solution was followed until the head of the volume was
clearly detected in the first portion of the duodenum (mouth
to duodenum time, MDT). The tablets were followed until
they lost their shape—they typically formed a disintegra-
tion cloud—and disappeared (i.e., DT), whether this
occurred in the esophagus, the stomach or the small
intestine.
After the images had been digitalized, a PC time counter
was used to estimate MST for both formulations, which
were compared for the standing or upright and horizontal
positions by analysis of the mean and the variance values
by t test for independent groups. Variance (S) is a measure
of how robust the mean value is as a function of the dis-
tribution of the individual values considered. Likewise,
MDTs for the drinkable solution and DTs for the tablet
formulation were compared for the two body positions of
the subjects by t test for dependent samples. Median and
ranked paired analysis by Wilcoxon test were also per-
formed. Nonparametric Spearman rank order correlation
test, with pairwise deletion of cases was used to associate
MST, MDT and DT with the age of the participants, and
within treatments.
Once the experiments were over, the subjects remained
in the Unit under clinical supervision for 2 h and were then
discharged and instructed to come back or call should they
experience any adverse events or discomfort during the
next week. During this period, patients were called back for
a new visit if any anatomic or functional abnormalities
were detected in the video deglutition images.
Results
Bioequivalence Study
The study protocol was successfully completed by 104
subjects, aged 26.7 ± 7.9 years, with a body mass index of
23.2 ± 2.1. Table 1 shows the main results for the phar-
macokinetic variables studied. When data for both
alendronate formulations were compared, AE(0–36 h) and
Rmax were found to be within the acceptable range for
bioequivalence, respectively 81.8–105.7 and 81.7–106.2.
Intrasubject variation for AE(0–36 h) was 60.3–61.8 % for
Rmax; the statistical power of the sample was 0.89 and
0.88, respectively, which is sufficient for establishing
bioequivalence.
Median AE(0–36 h) was very similar for both products;
121.9 lg for the drinkable solution and 124.4 lg for the
tablets; mean values were higher, especially for the tablets,
which also showed a greater SD. %CV was 78.1 % for the
drinkable solution and 88.1 % for the tablets (ie, 12.8 %
Fig. 1 Body position of the participants during the upper digestive tract transit study. Left standing position. Right bed rest (prone) position
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higher for the tablets). The distribution of the number of
cases according to AE(0–36 h) showed that in the
112.5–212.5 lg range, which represents the magnitude of
urinary alendronate excretion found with the highest fre-
quency (63 of 104 for the drinkable solution and 52 of 104
for the tablets), there were 21.2 % more subjects treated
with the drinkable solution than with the tablets (Fig. 2).
On the other hand, the distribution of cases treated with
tablets tended to be higher in subjects with the lowest
(\112.5 lg) or highest ([212.5 lg) levels of urinary
recovery. Above 412.5 lg, 9 patients were treated with
tablets and 3 with the drinkable solution. Median Rmax
values were 37.1 lg/mL for the drinkable solution and
41.1 lg/mL for the tablets. Variations in Rmax show a
similar pattern, with %CV being 16.9 % higher for the
tablets; this parameter, however, is less clinically relevant
for this type of product [23].
Mean urinary alendronate concentration did not differ
significantly between the two formulations at any of the
collection periods. For example, during the first hour uri-
nary alendronate concentration was 109.0 ± 302.5 lg/L
after the tablets and 177.3 ± 205.4 lg/L after the solution
(not significantly different). However, the variance was
significant lower with the solution (F test, p \ 0.05).
Overall, 62 nonserious adverse events were reported as
mild or moderate, with the exception of one case of severe
Table 1 Pharmacokinetic parameters from a bioequivalence study comparing single 70 mg dose taken either via a tablet or a drinkable solution
(0.7 %) in 104 healthy young men after an overnight fast and a 4 h postdosing fasting period
Formulation Tablet Drinkable formulation BE (IC90)
Alendronate urinary excretion after a single 70 mg administration
AE(0–36 h), lg, mean (SD) 167.3 (147.3) 140.7 (109.9)
AE(0–36 h), lg, median (min–max) 124.2 (8.8–818.8) 121.9 (32.1–919.9)
AE(0–36 h), %CV 88.1 78.1 81.8–105.7
Rmax, lg/mL, mean (SD) 54.4 (50.3) 47.3 (37.4)
Rmax, lg/mL, median (min–max) 41.9 (4.6–334.7) 37.1 (5.03–266.34)
Rmax, %CV 92.5 79.1 81.7–106.2
Tmax, h, mean (SD) 1.58 (0.67) 1.68 (0.72)
Tmax, h, median (min–max) 1.5 (0.13–3.5) 1.5 (0.63–5.0)
Bioequivalence between both formulations is within the acceptable range
Fig. 2 Individual curves of the
cumulative amount of
alendronate excretion in urine in
104 healthy young men after
receiving, in fasting conditions
([8 h before and 4 h after
administration), a single 70 mg
dose in a tablet ?240 mL of
plain water (left), or a single
70 mg/100 mL drinkable
solution ?140 mL of plain
water (right); truncated at 9 h
after dosing. From hours 9–36,
the cumulative amount is minor;
the shape of the curves does not
change
C. Go´mez Acotto et al.: Gastrointestinal Tract Transit Times 329
123
headache, which resolved without sequelae. Forty-one of
these events occurred during period 1 (in 30 of 106 sub-
jects) and 21 during period 2 (in 17 of 104 subjects). The
distribution of adverse events was similar for the tablet and
for the drinkable solution; 31 events were reported for each
formulation. Of these none was considered by the investi-
gators to be definitely related to the products. Five were
classified by the investigators as probably product related;
2 (headache and nausea) with the tablet and 3 (2 cases of
headache and 1 with diarrhea) with the solution. Other 23
events were classified possibly product related, 14 with the
tablet: headache (n = 6), hypophosphatemia (n = 3),
hyperbilirubinemia (n = 2) and hypocalcemia, myalgia
and pain of knee (n = 1 each), and 9 with the solution
hypophosphatemia (n = 4), headache (n = 2), myalgia
(n = 2) and vomiting (n = 1). The type and frequency of
these events are consistent with those described in the
summary product characterization of Fosamax.
Video Deglutition Study in Healthy Adults
Videos were examined after completion of all procedures.
Data from one subject were discarded because the contrast
material that remained after the first experiment precluded
an adequate follow-up of all experimental sequences. In
two subjects—a 66-year-old woman and a 68-year-old
man—previously unknown hiatus herniae were detected,
which did not affect transit times for either the tablet or the
drinkable solution. A 68-year-old woman from the bed rest
position group showed difficulties in the passage of the
tablet through the esophagus and quick disintegration once
the tablet had reached the stomach. In a 60-year-old man
who took the tablet in the standing position, the tablet stuck
to the esophagus and disintegrated there. Early tablet dis-
integration in the esophagus upon swallowing the formu-
lation in the bed rest position was also observed in a
52-year-old man. Neither of these two subjects met the
MST criteria. The video of a 52-year-old man revealed that
the tablet had remained in the esophagus for 8 min, then
passed intact through the stomach and the pylorus and did
not disintegrate at any time during the 20 min video fol-
low-up. A 51-year-old woman whose images showed a
‘‘waterfall’’ stomach had a very short MST, both with the
tablet and the drinkable solution. The same was observed
in a 40-year-old woman with a similar gastric image. In the
video of a 46-year-old woman, a diverticulum was detected
in the lower portion of the esophagus, and because the
subject had initially been administered the drinkable
solution formulation, the subsequent images were not clear
enough for calculating the tablet disintegration time.
Table 2 summarizes the mean, median, variance and
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MST was very short for the two formulations; although the
drinkable solution proved to be the one with the shortest
transit time, the differences between the two formulations
were not statistically significant when dosing under either
of the body positions studied (Table 3). However, the
variance and range were larger for the tablets than for the
liquid formulations. When the tablet transit time is asses-
sed, medians are smaller than means (Table 2), which
shows that the distribution curve does not behave normally
as a result of the high dispersion of the data (S) with tab-
lets. Therefore, the ranked analysis (Wilcoxon test Table 3)
of the MSTs shows that the MST for the drinkable solution
administered in the standing position is significantly
shorter than for the tablet (standing and prone position) or
the drinkable solution taken in the prone position, even
though they all have the same median value (5 s), which
suggests that delays are more likely to occur when dosing
in the prone position. Likewise, the drinkable solution is
also significantly faster than the tablet when dosed in the
prone position. Mean and median MST measured for the
standing position are faster for the drinkable solution but
the sample size does not provide enough power for statis-
tical significance between the parameters. Conversely, the
analysis of the variances did have statistical significance,
showing that variability in transit was much smaller after
taking the drinkable solution, for both body positions
studied. This is determined by the early disintegration of
the tablet in the esophagus or by a delay in its passage to
the stomach in some cases, which enhanced variance to
S = 12,567.5 s2 in the group of subjects who took the
tablet while standing, and to S = 29,715.1 s2 in the bed
rest group. For the tablet, the differences in body position
upon dosing were not significant in this small sample, and
the variance was double (p \ 0.09), which suggests that
this trend could be confirmed with a larger sample. Body
position upon dosing clearly did not affect the transit of the
drinkable solution to the stomach (Tables 2, 3). The vari-
ance for the drinkable solution taken in the bed rest posi-
tion is smaller than for the tablet, both for the standing and
the bed rest positions. The low p values may suggest a
trend in differences.
Regarding the MDT, access to the duodenum was quick
after swallowing 100 mL of alendronate solution but the
difference in access to the duodenum between both posi-
tions was not significant (p \ 0.75). Surprisingly, however,
variance was significantly smaller in the group examined in
the bed rest position (p \ 0.05), suggesting that the for-
mulation could be a good option for bedridden patients.
Indeed, with the drinkable formulation, the alendronate
was available in the intestine in\3 min on average, and no
test showed results longer than 10 min. On the other hand,
most of the alendronate tablets disintegrated in the stomach
as expected (differences between body positions were not
significant, p \ 0.79 for the means and p \ 0.32 for the
variances), including two cases in which the tablet
remained intact after dosing for 17 min (in the standing
position) and for more than 20 min (in the bed rest posi-
tion), and passed intact to the duodenum in the latter
subject. Three other cases of asymptomatic tablet disinte-
gration in the esophagus were observed. In addition, the
only significant influence of age was on the MDT within
the group that was administered the drinkable solution in
the bed rest position, with r = -0.53 (p \ 0.04; n = 11),
which indicates that transit might be somewhat slower in
older patients. Mean height of the subjects was 167.4 cm
(range 152–200 cm) and tended to correlate with the values
of MST of the tablet taken in the bed rest position
(r = 0.51; p \ 0.07). The body mass index of the subjects
did not correlate with any of the transit measurements
taken. The MST correlation coefficient was high, r = 0.79
Table 3 Statistical analysis of
the mouth to stomach transit
time (MST) as described in
Table 1
Significance probability was
calculated using Student’s t test
for independent groups for
mean (x) and variance (S) and












x 0.41 0.37 0.43
Md 0.52 0.61 0.31
S 0.09 0.001 0.001
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(p \ 0.02; n = 8) when comparing the groups who had
been administered the tablets and drinkable solution in the
bed rest position, suggesting that the transit for both for-
mulations is equally good when subjects have no apparent
motility problems. For the MST the group taking the
drinkable solution in the bed rest position also correlates
moderately with the group taking it in the standing position
r = 0.67 (p \ 0.02; n = 12). Finally, accessibility to the
duodenum with the drinkable solution tends to correlate
moderately r = 0.55 but not significantly in this study
(p \ 0.07; n = 12).
No adverse effects were reported during the study or the
week after the study.
Discussion
We show here that in young men under strictly controlled
conditions, the alendronate drinkable solution is bio-
equivalent to the reference tablets and therefore suitable for
the long term treatment of osteoporosis. In young healthy
subjects under optimal conditions (precise compliance with
dosing instructions, quantity and quality of water con-
sumed, no food intake, proper body position) the pharma-
cokinetics of the alendronate released from the tablet are
equivalent to those of the liquid formulation. As this type
of studies are usually done in healthy young volunteers this
may limit the conclusions to this group. However, we also
showed that there are differences between the two prepa-
rations when given to older adults which may have
important implications for the treatment of elderly patients
in clinical practice. Mean esophageal transit for the
drinkable alendronate solution is around 7–8 s, with the
mean small bolus transit velocity described in 6 s [24].
With the drinkable solution, the alendronate was delivered
in a completely soluble form to the first portion of the
intestine in\3 min on average, in both the standing and the
lying positions, and the longest time to reach the absorption
site was \10 min in all studied subjects, including those
with hiatus herniae. Hence, the recommended minimum
30 min postdosing fast is a prudent period to enable further
absorption of alendronate at the most suitable site, i.e., the
first portion of the intestine. Conversely, although the
tablet also disintegrates in \4 min on average, it some-
times remains intact in the stomach and parts of the tablet
can even remain in the esophagus. This potential greater
variability in the availability of the tablets to the absorption
site suggests that alendronate might be absorbed in places
were the mucosa is very sensitive. The findings also sug-
gest that the specific instructions for the administration of
the alendronate tablets (remaining upright for 30 min after
dosing, dosing with NLT 200 mL water) represent only a
minimum requirement which is not fully effective in some
patients. These considerations are not applicable to the
liquid formulation, which is delivered quickly to the
intestine irrespective of body position. Because volunteers
older than 70 years, who may have more difficulties in
swallowing, were not allowed by the CME to participate in
the study, we cannot extrapolate the results to this age
group.
In addition, the alendronate tablet used in this study was
the reference formulation with a fast disintegration time
manufactured by Merck Sharp & Dohme Limited, and
differences may be greater when generic tablets are used.
Although the tablets used here were slightly modified by
the test methodology, the fact that some units dissolved
early in the esophagus, while others appeared intact in the
duodenum seems to indicate that the tablets were neither
physically weakened nor strengthened to any considerable
extent by the contrast media used in this study. Moreover,
the generic alendronate tablets available in the market,
even when bioequivalent, have been questioned as a result
of potential differences in their in vitro disintegration time,
which can be as long as 13 min [25–28]. Such rate suggests
that the slower dissolution gradient of the solid generics
exposes the digestive walls to protracted high concentra-
tions of alendronate during a critical period, probably
affecting the local reactivity of the tissue and the tolera-
bility, or favoring the undesired interactions of the drug
with the intradigestive environment and/or contents [29].
So we agree with the authors who claim that even with
approved bioequivalence studies, generic tablets may per-
form differently in practice if their disintegration charac-
teristics and quality are not adequately controlled. A recent
article by Kanis et al. [30] report a dissimilar profile of
adverse effects, compliance and cost/utility variables when
switching to generic tablets of bisphosphonates. In fact, the
comparison of formulations under experimental conditions
such as bioequivalence studies may mask broader differ-
ences that can appear in practice. In the typical bioequiv-
alence test, healthy young adults are recruited and properly
trained to follow all dosing instructions, pay attention to
the warnings and drink adequate volumes of water. Usu-
ally, the postdosing fasting period is strictly controlled by
the staff and can be as long as 4 h, during which the
influence of delays in transit, disintegration or reflux on the
results can be compensated by a certain amount of late
absorption [31–36]. In practice such conditions are not at
all likely to occur.
The present study shows that in older subjects, admin-
istering alendronate via drinkable solution induces fewer
variations in the access to the intestine. In agreement with
this view, a 6 month placebo-controlled clinical study
involving 392 postmenopausal women treated with a dif-
ferent oral solution formulation (alendronate 70 mg/75 mL
plus extra water) showed that the urinary NTx corrected for
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creatinine and serum bone- specific alkaline phosphatase
reductions were (95 % confidence interval) -56.1 to -38.8
and -44.9 to -32.6, respectively, a range of variability
that is quite narrow for a bisphosphonate and entirely
within the effective levels. As expected, the tolerability of
the oral solution in such sample was slightly lower than for
the placebo, but the rate of upper digestive tract adverse
events that were serious or led to discontinuation of treat-
ment was similar [37].
Finally, the pharmaceutical drinkable solution of
alendronate taken with no added water as in this study
precludes interactions with minerals that can occur when
patients use water, whether tap or bottled, to swallow
(dissolve) alendronate tablets [38].
The 100 mL volume of the test formulation was enough
to enable the alendronate to be available in the intestine
rapidly; this agrees with physiological studies of water
emptying from the stomach, according to which even
smaller volumes can be emptied faster [39]. Moreover, the
addition of synthetic viscosity agents to the drinkable
solution formulation enables it to progress through the
digestive system with some syrup-like properties, that is, to
spread a little bit more slowly than water in the stomach
and to remain for a longer time in the first portion of the
intestine. This thinly viscous mass may make completely
soluble alendronate molecules available for a longer time at
the proper absorption site. Furthermore, even in cases in
which only partial volumes are delivered to the duodenum
within the 30 min fasting period, such quantity is enough to
allow the expected average absorption of around 1 % of the
active principle. Besides volume considerations, the calorie
content of the alendronate solution is negligible, and it is
probable that if administered after cooling in the refriger-
ator, transit may be even quicker, improving palatability at
the same time [39–41].
Oral solution formulations do not enhance alendronate
absorption, as proved by bioequivalence studies vs. the
tablets, provided the comparison test has been conducted
under adequate experimental conditions, yet the drinkable
solution of alendronate is less affected by certain variables
in practice, as shown in this study.
The video deglutition radiological test used in this study
can be considered in patients treated with alendronate who
do not appear to respond or report digestive intolerance.
Transit problems with the tablet formulation can be
asymptomatic and more frequent than one might expect.
Conveniently, as it is the transportation mode and not the
molecule that is the cause of the unsatisfactory result,
patients should remain under treatment with alendronate
and change the vehicle of administration before switching
to a different active compound which might be less
effective, have uncertain safety parameters or be more
expensive.
In conclusion, the alendronate solution has rapid access
to the absorption site and is less subject to transit problems
than the tablet formulation. Therefore, alendronate, the
drug of choice for the treatment of osteoporosis in many
countries, can be administered on weekly basis in an
optimized manner even in bedridden patients.
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